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The reactivates of human sera with uninduced and phorbol ester (TPA)-induced human herpesvirus-8 (HHV-8)-infected
BCBL-1 cells were examined by immunofluorescence assay (IFA) and by radioimmunoprecipitation reactions (RIP). The
seroprevalence of HHV-8 infections is low in the United States general population and only low levels of HHV-8 antibodies
were detected in the seropositive sera. In contrast, high levels of antibodies against HHV-8 lytic and latent antigens were
detected by IFA in the sera from HIV1 Kaposi’s sarcoma (KS)-positive individuals. These sera recognized several proteins and
glycoproteins from BCBL-1 cells in RIP reactions. Two types of antibody responses were detected in the sera from HIV1 KS2
homosexual men. In majority of the sera with and without detectable HHV-8 DNA in the peripheral blood mononuclear cells
(PBMC), significantly low levels of HHV-8 antibodies were detected by IFA. These sera recognized only a subset of HHV-8
proteins and glycoproteins in RIP reactions. In contrast, in a subgroup of sera from HIV1 KS2 homosexual men, higher levels
of IFA antibodies against HHV-8 lytic and latent antigens were detected. These sera also recognized several viral proteins
and glycoproteins in RIP reactions. These results suggest that antibody response profiles to HHV-8 infection vary signifi-
cantly and serologic assays to detect antibody responses to a panel of both lytic and latent antibodies may be required for
maximum sensitivity. Screening of a cDNA library from TPA-induced BCBL-1 cells with an HIV1 KS1 serum identified cDNAs
encoding 12 HHV-8 proteins. Further characterization of these HHV-8 proteins would define the HHV-8 antigens useful for
seroepidemiological studies and in discriminating lytic, latent, past, and/or reactivation infections. © 1998 Academic Press
INTRODUCTION
The newly identified human herpesvirus-8 (HHV-8) [or
Kaposi’s sarcoma-associated herpesvirus (KSHV)] DNA
has been detected in more than 95% of Kaposi’s lesions
studied, in both HIV-negative and HIV-positive individu-
als and in all clinical subtypes of KS (Ambroziak et al.,
1995; Chang et al., 1994, 1996; Dupin et al., 1995; Huang
et al., 1995; Staskus et al., 1997). In addition, HHV-8
sequences have been detected in body cavity-based
B-cell lymphomas (BCBL) and several B-cell lines have
been established from the BCBL tumors (Cesarman et
al., 1995a,b; Renne et al., 1996). The BC-1 and HBL-6 cell
lines carry both HHV-8 and Epstein–Barr virus (EBV).
Upon phorbol ester (TPA) induction, a high level of EBV
was reactivated from these cells with only a small
amount of HHV-8 DNA replication (Cesarman et al.
1995a,b,; Moore et al., 1996a). BCBL-1 cells carry only
HHV-8 and a lytic cycle can be induced by TPA (Renne et
al., 1996). Sequences of about 140 kb HHV-8 DNA en-
coding more than 80 complete open reading frames
(ORFs) have been published recently (Neipel et al., 1997;
Russo et al., 1996). These HHV-8 ORFs are identified as
ORFs 4 to 75 by their homology to ORFs of herpesvirus
saimiri (HVS), a simian herpesvirus. HHV-8 also encodes
19 unique ORFs designated with a prefix K (Neipel et al.,
1997; Russo et al., 1996). BCBL-1 cells were used in
immunofluorescence (IFA) and Western blot assays to
measure the latent and lytic antibody responses to
HHV-8 in human sera (Gao et al., 1996a,b; Kedes et al.,
1996; Koelle et al., 1997; Simpson et al., 1996; Smith et al.,
1997). HHV-8 seroprevalence varies according to the
country of origin, with a higher prevalence in Africa
(53–90%) (Gao et al., 1996a; Simpson et al., 1996). How-
ever, there are discrepancies in the incidence of HHV-8
infection reported by these studies and only a little is
known about the antigens recognized by the sera. Iden-
tification and characterization of HHV-8 proteins recog-
nized by human sera are fundamental to a rational un-
derstanding of the biology of HHV-8, its role in KS and
other human diseases, and for diagnostic purposes. As
an initial step, we tested sera in immunofluorescence
and immunoprecipitation reaction assays with unin-
duced and TPA-induced BCBL-1 cells. Sera from HIV1
and KS2 individuals and a subgroup of HIV1 KS2 indi-
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viduals showed higher levels of antibodies against
HHV-8 lytic and latent antigens. These sera immunopre-
cipitated several HHV-8-specific polypeptides and glyco-
proteins. The intensity of polypeptide bands increased
with IFA titer. In contrast, most of the HIV1 KS2 patients
showed significantly low HHV-8 antibody titers, with and
without HHV-8 DNA in their peripheral blood, and recog-
nized only a subset of HHV-8 proteins. Screening of a
cDNA library from TPA-induced BCBL-1 cells with an
HIV1 KS1 serum identified cDNAs encoding 12 HHV-8
proteins.
RESULTS
HIV1 KS1 and HIV1 KS2 sera show two types
of HHV-8 antibody responses in IFA
All sera were tested by IFA with uninduced and TPA-
induced BCBL-1 (HHV-81) cells, with TPA-induced BJAB
cells, and with TPA-induced P3HR-1 EBV producer cells.
Specific granular punctate nuclear fluorescence with the
majority (.80%) of uninduced BCBL-1 cells and bright
cytoplasmic fluorescence with about 30% of TPA-induced
BCBI-1 cells were considered as recognizing latent and
lytic HHV-8 antigens, respectively (Kedes et al., 1996;
Lennette et al., 1996; Smith et al., 1997). About 3 to 8% of
cells also showed moderate cytoplasmic fluorescence
and to determine whether this was due to the reactivity
with lytic cycle HHV-8 antigens, expression of lytic cycle
HHV-8 proteins ORFs 22, 25, and 26 was examined by
RT–PCR. The uninduced BCBL-1 cells were positive for
these three ORFs and a higher quantity was detected
from TPA-induced cells (data not shown). These results
suggested that like P3HR-1 EBV producer cells and
B95-8 (Kieff, 1996; Rickinson and Kieff, 1996), the BCBL-1
cell is a producer cell line with a low percentage of
uninduced cells spontaneously producing lytic antigens.
Though sera were tested with a starting dilution of
1:10, several sera showed nonspecific fluorescence at
1:10 and 1:20 dilutions with BCBL-1 and BJAB cell.
Hence, sera showing a reactivity at a dilution of 1:40 and
above were considered positive and all positive sera
were retested at least three times. Several sera from
HIV1 KS2 individuals, HIV2 healthy adults, and healthy
children did not react with uninduced and TPA-induced
BCBL-1 cells. This suggested that the reactivities of HIV1
KS1 sera were not against TPA-induced host cell pro-
teins and were directed against HHV-8 lytic cycle-asso-
ciated proteins induced by TPA. Ninety percent of sera
from children and healthy adult men were positive for
EBV-VCA antibodies and their titers ranged from 1:80 to
1:10,240, with a geometric mean titer (GMT) of 1:977. In
contrast, none of the 110 sera from children (age 1–5)
were positive for HHV-8 antibodies. Among the 120 sera
from age-matched HIV2 healthy adult men tested, only 9
(8%) were positive for HHV-8 lytic antibodies and 4 of
these 9 sera (3.3%) were also positive for antibodies
against latent antigens and exhibited LANA type fluores-
cence. The antibody titers were also low, with GMTs of
53 and 47 for lytic and latent antibodies, respectively
(Table 1). In contrast, the HHV-8 antibody titers from 44
HIV1 KS1 individuals with uninduced and induced
BCBL-1 cells ranged from 1:40 to 1:10,240, with GMTs of
1:105 and 1:449, respectively (Table 1). When PBMC from
these patients was examined, HHV-8 DNA was detected
TABLE 1
Reactivity of Human Sera in Immunofluorescence Assay with HHV-8-Infected BCBL-1 Cells
Sera from No. tested
No. positive with
TPA-induceda cells
(%)
GMT
(range)b
No. positive with
uninduced cells
(%)
GMT
(range)
No. with PCR-
positive PBMCs
(%)
HIV1 KS1 44 43 (98) 449 (40–10,240)c 41 (93) 105 (40–1,280)e 27 (61)
HIV1 KS2 47 28 (60) 84 (40–1,280)c 16 (34)g 57 (40–320)e 12 (26)
Low seropositive 23 55 (40–160)d 11 40 (40–80)f 9
High seropositive 5 484 (320–1,280) 5 159 (80–320) 3
Healthy adults 120 9 (8) 53 (40–160) 4 (3) 47 (40–80) ND
Children (ages 1–5 years) 110 0 — 0 — ND
Note. Sera were tested for HHV-8 reactivity with uninduced and TPA-induced BCBL-1 cells by IFA. Specific reactivity at $1:40 dilution was
considered positive for IFA. ND, not done.
a Phorbol ester.
b Geometric mean titer.
c–f Comparison of titers of anti-HHV-8 antibodies between groups was performed on log-transformed titers using Wilcoxon two-sample test and
Kruskal–Wallis test.
c HIV1 KS1 vs HIV1 KS2 lytic antibody response; P 5 0.0001.
d HIV1 KS1 vs low seropositive HIV1 KS2 lytic antibody response; P 5 0.0001.
e HIV1 KS1 vs HIV1 KS2 latent antibody response; P 5 0.0001.
f HIV1 KS1 vs low seropositive HIV1 KS2 latent antibody response; P 5 0014.
g All sera positive for LANA type fluorescence with uninduced cells were also positive for lytic antibodies. Sera reactive only with uninduced cells
were not detected.
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in 27 samples (27/44, 61%). Absorption with TPA-induced
EBV producer cells (P3HR-1) did not alter the reactivities
of these sera (data not shown), thus suggesting no in-
terference due to cross-reacting antibodies under the
conditions of our assays. Furthermore, though all KS
patients were also positive for EBV-VCA, with antibody
titers ranging from 1:80 to 1:10,240 (GMT, 786), there was
no correlation between EBV-VCA and HHV-8 titers.
Among the 47 HIV1 KS2 gay men examined, 12 were
positive for HHV-8 DNA in their PBMC (12/47, 26%), 28 of
47 (60%) were positive for lytic antibodies, and 16 of 47
(34%) sera were seropositive for LANA type IFA antibod-
ies. All 16 sera positives for LANA type fluorescence
were also positive for lytic antibodies. The overall geo-
metric mean antibody titers against latent and lytic anti-
gens (1:57 and 1:84) detected in these sera were signif-
icantly lower than the GMT detected in HIV1 KS1 pa-
tients (P 5 0.0001, Wilcoxon two-sample test. Table 1).
Interestingly, two types of antibody responses were de-
tected in these HIV1 KS2 patients. Most of the sera
(23/28, 82%) showed low levels of HHV-8 antibodies with
uninduced (GMT, 40) and induced BCBL-1 cells (GMT,
55), which was significantly lower than the GMT detected
in HIV1 KS1 patients (P 5 0.0014 and P 5 0.0001, re-
spectively. Table 1). PBMC from 9 patients in this group
(9/23, 39%) were positive for HHV-8 DNA. Another group
of 5 HIV1 KS2 patients (5/28, 18%) showed higher levels
of HHV-8 lytic antibodies (.1:320) and PBMC from 3 (3/5,
60%) were positive for HHV-8 DNA by PCR. The lytic
HHV-8 antibody titers for the 5 patients were 1:320,
1:1280, 1:640, 1:640, and 1:640, respectively, with twofold
lower antibody titers for LANA type fluorescence (Table
1). There were no statistical differences when the GMT
against latent and lytic antigens detected in the 5 HIV1
KS2 high HHV-8 antibody sera was compared with the
GMT detected in HIV1 KS1 patients (Table 1). The 23
HIV1 KS2 patients with low HHV-8 antibodies had a
mean CD41 T-cell level of 326 (range 116–697) and the 5
HIV1 KS2 patients with high HHV-8 antibodies had a
mean CD41 T-cell level of 130 (range 49–295).
Serological responses against HHV-8 are directed
against a number of HHV-8 proteins
To define the HHV-8 proteins recognized by the above
human sera, RIP reactions with uninduced and TPA-
induced BCBL-1 cells labeled with [35S]methionine 1
cysteine (3 to 4 days postinduction) were done. A com-
posite of representative examples is shown in Fig. 1. A
polypeptide of about 49 kDa was recognized weakly by
all sera from uninduced and TPA-induced BCBL-1 (Fig. 1)
and D6 cells (data not shown). This was considered
nonspecific or due to cross-reacting antibodies. Besides
this reaction, sera from HIV1 and HIV2 KS2 adults neg-
ative for HHV-8 antibodies by IFA did not show any
specific reaction by immunoprecipitation (Fig. 1, lanes 1
and 2). From TPA-induced cells, sera from HIV1 KS1
individuals recognized at least 20 polypeptides (Fig. 1,
lanes 3–6) and among these, polypeptides with approx-
imate molecular weights of 155, 145, 125, 116, 105, 90, 74,
60, 55, 50, 45, 41, 38, 34, and 29 kDa were prominent (Fig.
1, lanes 4 and 6). Only a weak reaction was seen with
uninduced BCBL-1 cells and a limited number of
polypeptides (225, 145, 125, 116, 105, 74, 70, 55, and 29
FIG. 1. Reactivities of human sera with HHV-8-infected uninduced and TPA-induced BCBL-1 cells in RIP reactions. Uninduced BCBL-1 cells (lanes
1, 3, 5, 7, and 9) and TPA-induced BCBL-1 cells (lanes 2, 4, 6, 8, 10, and 11–14) were labeled with [35S]methionine and cysteine and lysates were reacted
with sera. Lanes 1 and 2: HIV2 and KS2 and HHV-8 antibody-negative serum. Lanes 3–6: HIV1 KS1 individuals’ sera. Lanes 7–11: HIV1 KS2 sera
with low HHV-8 antibodies. Lanes 12–14: HIV1 KS2 sera with high HHV-8 antibodies. Samples were analyzed on 9% acrylamide cross-linked with
N-N9-diallyltartardiamide. Standard molecular weight markers were included in parallel lanes. Numbers indicate approximate molecular mass (kDa)
of HHV-8 polypeptides immunoprecipitated. IFA titer indicates antibody titer of sera as measured in an immunofluorescence assay with acetone-fixed
TPA-induced HHV-81 BCBL-1 cells.
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kDa) were immunoprecipitated (Fig. 1, lanes 3 and 5).
Similar to these HIV1 KS1 sera, the five sera from HIV1
KS2 individuals with higher HHV-8 IFA antibody titers
recognized at least 20 polypeptides from induced cells
(Fig. 1, lanes 12 to 14). Absorption with TPA-induced EBV
producer cells (P3HR-1) did not alter the reactivities of
these sera (data not shown), thus suggesting no inter-
ference due to cross-reacting antibodies under the con-
ditions of our assays. In contrast, sera from HIV1 KS2
individuals with HHV-8 in their PBMC and with low reac-
tivity in IFA (titer 1:40) recognized only a subset of HHV-8
proteins with approximate molecular weights of 116, 74,
50, 45, and 29 kDa (Fig. 1, lanes 7 to 11). Similar reactions
were also seen with sera from HIV2 and KS2 adult men
with low HHV-8 antibody titers (data not shown). These
bands were visible only after long exposure of the auto-
radiographs. The 155-kDa polypeptide was recognized
only by sera with an IFA titer of .1:320.
Analysis of HHV-8 glycoproteins immunoprecipitated
by human sera
Since glycoproteins of herpesviruses were shown to
be good targets for human serological responses, we
tested the human sera with [3H]glucosamine-labeled un-
induced D6 (HHV-82), uninduced, and TPA-induced
BCBL-1 (HHV-81) cells. Equal amounts of TCA-precipita-
ble counts (5 3 105 cpm) of cell lysates were used and
representative results are shown in Figs. 2A and 2B. No
specific reactivity was seen with HHV-8-negative D6
cells (Figs. 2A and 2B, lanes 1, 4, 7, and 10) and the
reactivity with a high molecular weight polypeptide rec-
ognized by all HHV-81 and HHV-82 sera (Figs. 2A and
2B, arrow) was considered nonspecific. Similar reactions
were seen with HHV-82 BJAB cells (data not shown). A
barely detectable glycopolypeptide of about 49 kDa was
recognized by all sera from uninduced and TPA-induced
cells and was considered nonspecific or due to cross-
reacting antibodies. Besides these minimal reactivities,
HIV1 HHV-82 sera did not show any specific reactivity
with BCBL-1 cells (Fig. 2B, lanes 1–9). In contrast, HIV1
KS1 sera (Fig. 2A, lanes 1–9) and HIV1 KS2 sera with
high HHV-8 antibodies (Fig. 2A, lanes 10–12) immunopre-
cipitated glycopolypeptides of 128, 116, 105, 80, 75, 65,
60–55, 50, 45, 41–38, 34–32, and 29 kDa from uninduced
(Fig. 2A, lanes 2, 5, 8, and 11) and TPA-induced (Fig. 2A,
lanes 3, 6, 9, and 12) BCBL-1 cells. The intensity of
glycopolypeptide bands increased with IFA titer. Though
equal TCA counts were used for these immunoprecipi-
tation reactions, the intensity of bands recognized from
induced BCBL-1 cells was much higher than that from
bands from uninduced BCBL-1 cells, suggesting in-
creased synthesis of these glycopolypeptides after TPA
induction.
In contrast to these results, HIV1 and HIV2, KS2 low
HHV-8 antibody titer sera (,1:160) weakly recognized
the glycopolypeptides of 116, 80, 60–55, and 51 kDa (Fig.
2B, lane 12). Autoradiographs shown here were exposed
for 4 weeks and the glycoproteins immunoprecipitated
by these sera were barely detected even after 8 weeks of
exposure. Experiments with inhibitors of glycosylation
and glycosidic enzymes indicate the presence of sugar
residues in these proteins (data not shown), eliminating
the possibility of incorporation of radiolabels into these
proteins after the metabolic breakdown of the [3H]glu-
FIG. 2. (A and B) Reactivities of sera with HHV-8 glycoproteins. Cells were labeled with [3H]glucosamine. Lanes 1, 4, 7, and 10: uninduced
HHV-8-negative D6 cells. Lanes 2, 5, 8, and 11: uninduced BCBL-1 cells. Lanes 3, 6, 9, and 12: TPA-induced BCBL-1 cells. The arrow indicates the
235-kDa glycoprotein from all three cell lysates immunoprecipitated by all sera, irrespective of their HHV-8 antibody status. (A) Lanes 1 to 9: HIV1
KS1 sera. Lanes 10–12: HIV1 KS2 serum with high HHV-8 antibodies. (B) Lanes 1 to 9: HIV1 KS2 and HHV-8 antibody-negative sera. Lanes 10–12:
HIV1 KS2 serum with low HHV-8 antibodies. Samples were analyzed on 9% acrylamide cross-linked with N-N9-diallyltartardiamide. Standard
molecular size markers were included in parallel lanes. Numbers indicate approximate molecular weights (kDa) of HHV-8 polypeptides immuno-
precipitated. IFA titer indicates antibody titer of sera as measured in an immunofluorescence assay with acetone-fixed TPA-induced HHV-81 BCBL-1
cells and with TPA-induced EBV producer P3HR-1 cells.
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cosamine. The ability of sera to immunoprecipitate gly-
coproteins from BCBL-1 cells was not related to EBV VCA
titers, since many sera with high EBV VCA titers did not
recognize HHV-8 proteins (Fig. 2B, lanes 1–9). The reac-
tivities of human sera with the HHV-8 glycoproteins sug-
gested that HHV-8 glycoproteins may serve as good
target antigens for the development of sensitive and
highly specific serological assays.
Identification of genes encoding immunogenic
proteins of HHV-8
To identify the genes encoding immunogenic HHV-8
proteins, a serum from HIV1 KS1 individual with high
HHV-8 antibodies (1:10,240) in IFA was used to screen
the cDNA library from induced BCBL. After four screen-
ings, 56 cDNA clones were isolated and released in
plasmid forms by cocultivation with the helper phage.
Overlapping clones of these cDNAs (both orientations)
were sequenced. Sequences were analyzed for ORFs
and, comparison with published genomic HHV-8 se-
quence identified 12 ORFs. These are: ORFs 6, 8, 9, 25,
26, 39, 59, 65, 68, 73, K8.1A, and K8.1B and the predicted
molecular weights of proteins encoded by the full-length
ORFs are given in Table 2. The putative functions for
some of these ORFs are designated by comparison with
other herpes virus ORFs and these are ORF6, ssDNA
binding protein; ORF-8, glycoprotein gB; ORF-9, DNA
polymerase; ORF25, major capsid protein; ORF26, minor
capsid protein; ORF59, DNA replication protein; ORF65,
capsid protein (Lin et al., 1997; Simpson et al., 1996); and
ORF73, putative LANA antigen (Rainbow et al., 1997). All
these cDNA-encoded proteins were in-frame with the
35-aa b-galactosidase fusion protein, thus suggesting
specific reactivity with HHV-8 ORFs.
The complete ORF 65 is encoded by the cDNAs and in
the other ORF cDNAs the length of ORFs ranged from
280 to 800 amino acids. However, identification of protein
in the cDNA by HIV1 KS1 serum suggests that they
encode the immunogenic part. ORF 65 is identified by
other studies as immunogenic, which was recognized by
about 85% of HIV1 KS1 sera (Lin et al., 1997; Simpson et
al., 1996). ORF 73 is identified as responsible for the
majority of the LANA type reactivities of sera (Rainbow et
al., 1997). Four cDNA clones in the above screening
encode for a novel HHV-8 glycoprotein, ORF K8.1. The
genomic ORF 8.1 is 197 aa long, with a N-terminal signal
sequence and without any transmembrane sequence.
However, comparisons of two full-length cDNA se-
quences show ORFs encoded by spliced messages (B.
Chandran et al., manuscript in preparation). One cDNA
encodes for an ORF designated K8.1.A, 228 aa long, a
typical class I glycoprotein with a cleavable signal se-
quence(s), a transmembrane domain (TM), and four pu-
tative N-glycosylation sites (N). The splicing event has
generated the transmembrane domain not seen in the
genomic ORF. Another cDNA encodes K8.1.B, an ORF of
167 aa, sharing similar amino and carboxy termini with
K8.1.A ORF. The splice acceptor sites for both cDNAs are
the same; however, the donor site for K8.1.B cDNA is
upstream of the splice donor site in K8.1.A cDNA. This
has resulted in an in-frame deletion (B. Chandran et al.,
manuscript in preparation).
DISCUSSION
To measure the human antibody responses against
HHV-8 antigens associated with latent and lytic replica-
tive cycles, BCBL cells carrying only HHV-8 or both
HHV-8 and EBV were used in IFA and Western blot
assays (Gao et al., 1996a,b; Kedes et al., 1996; Koelle et
al., 1997; Simpson et al., 1996; Smith et al., 1997). These
studies suggest that HHV-8 seroprevalence in the nor-
mal population varies according to the country of origin,
reflecting the differences in incidence of classical KS.
Our studies and others demonstrate that the seropreva-
lence of HHV-8 infections is low in the United States
general population and only low levels of HHV-8 antibod-
ies were detected. However, there are discrepancies in
the incidence of HHV-8 infection reported by these stud-
ies and only a little is known about the antigens recog-
nized by the sera.
Higher HHV-8 seropositivity was reported among HIV1
KS2 and HIV2 KS2 individuals in a study by Lennette et
al., (1996). This study also used TPA-induced BCBL-1
cells in IFA and 96% of AIDS–KS patients from the United
TABLE 2
HHV-8 ORFs Encoded by cDNAs Identified by an HIV1 KS1 Seruma
HHV-8 ORFs
encoded
by cDNAs
Amino acids
in the full-length
genomic ORFsc
Predicted molecular
weight (kDa) encoded
by the full-length
ORFsc
6 1133 130
8 845 94
9 1012 113
25 1376 153
26 305 34
39 401 45
59 396 43
65 170 18
68 545 60
73 1162 135
K8.1Ab 228 25
K8.1Bb 167 19
a The cDNA library in ZAPII was constructed by using mRNA isolated
from TPA-induced BCBL-1 cells. This library was screened with an
HIV1 KS1 serum. Immunoreactive phages were picked and purified by
four subsequent steps of screening. The identified cDNAs were re-
leased into the plasmid forms, sequenced, and compared with the
sequences in the data bank.
b ORFs encoded by spliced messages.
c From Russo et al. (1996) and Neipal et al. (1997).
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States and 100% of classic patients from Africa were
positive for lytic antigens. Only 52% of United States
AIDS–KS patients were positive for latent antigens,
which is lower than the 81–83% positivity for United
States AIDS–KS reported by Kedes et al. (1996) and Gao
et al. (1996a, b). In contrast, 100% of African AIDS–KS
patients were positive for latent antigens. HHV-8 sero-
positivity rates reached 90–100% in HIV-infected homo-
sexual cohorts from the San Francisco area, which is
higher than reported by others and by us. In addition,
seroprevalence in the normal adult population was re-
ported to be about 20–30%. These sera were tested only
at a 1:10 dilution and the titers were not reported. In the
recent studies by Simpson et al. (1996) and Lin et al.
(1997) using HHV-8 ORF 65, 84% of sera from KS patients
recognized ORF 65 protein and 82% reacted with LANA.
About 30% of HIV1 KS2 homosexual men, 3–5% of blood
bank donors from the United States and the United King-
dom, and 53% of HIV1 and HIV2 sera from Uganda were
positive by these two assays. The reason for the discrep-
ancies in the serological studies is not clear and maybe
due to the different assay systems used and the popu-
lations studied. Lennette et al. (1996) tested the sero-
prevalence in the general population only at a 1:10 dilu-
tion of the sera. In our studies, though sera were tested
with a starting dilution of 1:10, several sera showed
nonspecific fluorescence at 1:10 and 1:20 dilutions with
BCBL-1 and BJAB cells. These nonspecific reactions
were seen even using the mouse anti-human monoclo-
nal antibodies as described by Lennette et al. (1996)
(data not shown). Hence, we considered sera showing a
reactivity at 1:40 and above positive. In our studies, all
sera positives for lytic antibodies were also positive for
latent antibodies and no sera exhibiting only LANA type
fluorescence were detected. Detection of a higher per-
centage of lytic HHV-8 antibodies than the antibodies
against latent antigens by IFA (Table 1) suggests that
detecting LANA type fluorescence may be specific yet
may not be sensitive, and seroepidemiological studies
should include measurement of both types of antibody
responses.
The Simpson et al. (1996) and Lin et al. (1997) studies
identified HHV-8 ORF 65 as an immunogenic lytic cycle-
associated protein. However, not all HIV1 KS1 sera
showed positive reaction with the ORF 65 protein, sug-
gesting that an immunodominant antigen needs to be
used. As shown in our studies, humoral responses are
directed against a number of HHV-8 proteins, and a
majority of HIV1 KS2 individuals have low titers of HHV-8
antibodies, recognizing only a subset of viral proteins.
Hence it is critical to use antigens detecting the persist-
ing antibody responses for studies of seroprevalence.
HHV-8 proteins identified here represent soluble pro-
teins enriched by our detergent extraction procedure and
many insoluble proteins may have been removed from
the antigen preparation. The use of Protein A agarose
precludes the detection of any polypeptides recognized
by IgM antibodies. Similarly, BCBL-1 cells collected after
4 days of TPA induction used in these studies may
overrepresent viral structural proteins and HHV-8
polypeptides detected in these studies may not fully
represent HHV-8 early viral proteins. Hence, the number
of polypeptides identified here represents a minimum
estimate for the number of HHV-8 proteins eliciting anti-
body response in humans. Despite these limitations, our
studies show that at least 20 electrophoretically distinct
polypeptides were immunoprecipitated by the sera from
HHV-8-infected cells, but not from uninfected cell ex-
tracts. These reactivities show that antibody responses
against HHV-8 are directed against a variety of HHV-8-
specific proteins, as in other herpesviruses. Gao et al.
(1996b) used the BC-1 cell line (HHV81, EBV1) in a
Western blot assay and identified a 234/226 kDa doublet
protein associated with the nuclei of uninduced cells as
a HHV-8-specific latency-associated protein in their se-
rological assay. In the RIP reactions, a 225-kDa polypep-
tide was observed from uninduced cells (Fig. 2, lanes 3,
4, 5, 14) and could represent the 234/226 kDa protein
observed by Gao et al. (1996b). A weaker reaction in RIP
reactions could be due to poor solubility of this protein.
Our data also indicate differential responses against
different HHV-8 antigens. For example, all HIV1 KS1 sera
and the five HIV1 KS2 sera with higher HHV-8 antibodies
recognized the 155- kDa polypeptide, whereas none of
the HIV1 KS2 sera with low titer HHV-8 antibodies did
(Fig. 1). Similarly, HIV1 KS1 HHV-81 individuals recog-
nized at least 12 HHV-8-specific glycoproteins and
among these, only the glycoproteins of 110, 80, 60–55,
and 50 kDa were very weakly recognized by HIV1 KS2
sera (Fig. 2B). This suggests that responses against a
specific subset of HHV-8 proteins may be short-lived and
may rise during active viral replication. For example,
reactivity of a serum with only 110- and 50-kDa glycopro-
teins but not with the 55-, 38-, and 34-kDa glycoproteins
may be suggestive of past infection. Reactivity with all
these glycoproteins would suggest recent and/or reacti-
vation infection. Identification of genes encoding these
HHV-8 proteins and examining large numbers of sera
from HIV1 KS1 and HIV1 KS2 HHV-81 individuals with
these cloned and expressed genes would define the
HHV-8 antigens that can discriminate past or present or
reactivation infection. The partial list of genes identified
here is an initial step toward these goals. The number of
cDNAs recognized by an HIV1 KS1 serum here repre-
sents a minimum estimate for the number of HHV-8
proteins eliciting antibody response in humans. ORFs 65
and 73 were identified by other investigators as immu-
nogenic lytic and latent antigens, respectively (Simpson
et al., 1996; Rainbow et al., 1997). Direct comparison of
predicted molecular weights of proteins encoded by the
full-length ORFs (Table 2) with the molecular weights of
proteins recognized by human sera is not possible due
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to the posttranslational modifications of proteins in vivo.
Further characterization of these HHV-8 proteins would
define the HHV-8 antigens useful for seroepidemiologi-
cal studies and in discriminating lytic, latent, past, and/or
reactivation infections. In ongoing studies, K8.1A ORF
(glycoprotein) expressed as a GST fusion protein was
tested in Western blot assays. The results show that the
antibodies against K8.1A ORF persist in HHV-8-infected
individuals and testing the antibodies by this ORF pro-
vides a very sensitive and specific HHV-8 serological
assay (B. Chandran et al., manuscript in preparation).
High levels of antibodies against HHV-8 lytic and la-
tent antigens in HIV1 KS1 patients and low levels of
antibodies in the majority of HIV1 KS2 individuals were
detected in our studies. The limited number of polypep-
tides recognized by the majority of HIV1 KS2 sera sug-
gests that responses against these proteins may be
persisting. The apparent quantity of HHV-8 proteins and
glycoprotein immunoprecipitated by the sera correlated
with the increase in IFA titer, which may be indicative of
possible stimulation of antibody responses in these in-
dividuals. Stimulation may occur either due to viral rep-
lication (reactivation infection) or due to polyclonal stim-
ulation. Since HHV-8 was isolated from the cell-free sa-
liva of some of the HIV1 KS1 patients tested in the
present study (Koelle et al., 1997), this suggests that
reactivation could attribute to the detection of higher
HHV-8 antibody titer (.1:320). Using Gardella gel ana-
lyzes, Decker et al. (1996) also have detected linear
forms of HHV-8 viral genome in PBMC from KS patients,
an indication of HHV-8 viral replication in these patients.
Studies including ours (Cesarman et al., 1996; Staskus et
al., 1997; Smith et al., 1997) have also detected mes-
sages encoding HHV-8 lytic antigens in KS lesions. A
subset of HIV1 individuals reported here showed higher
levels of HHV-8 lytic antibodies and three (3/5) were
positive for HHV-8 DNA. This group could represent
patients with HHV-8 lytic replication.
The relationship between the detection of increased
levels of HHV-8 antibodies and AIDS–KS is not clear at
present. The Gao et al. (1996a,b) studies show that 21 of
the 40 HIV1 patients seroconverted to LANA type anti-
bodies 6 to 75 months before the clinical appearance of
KS, suggesting that the rise in antibodies against LANA
may also suggest an increase in latently infected endo-
thelial cells, B cells, and other cells and/or increase in
the transformed cells expressing latency-associated pro-
teins. These patients were not tested for lytic antibody
responses. Our studies have so far not detected low lytic
antibody responses and high LANA type latency-associ-
ated antibodies. Taken together, these data suggest that
the development of KS may be associated with HHV-8
reactivation and detection of higher levels of lytic and/or
latent antibody responses may indicate tumor develop-
ment and/or progression. In another study, 71% of HIV
patients with KS were shedding HHV-8 in saliva and
showed statistically significant higher HHV-8 lytic anti-
bodies than the HIV patients without KS (Koelle et al.,
1997). HHV-8 was detected in the saliva of only 15% of
HIV patients without KS. The amounts of HHV-8 DNA
were 2–4 logs lower than those detected in HIV1 KS1
patients’ saliva. This also supports the theory that reac-
tivation of HHV-8 may precede the development of clin-
ical KS.
Since the 23 HIV1 KS2 patients with low HHV-8 anti-
bodies have a mean CD41 T-cell level of 326 (range
116–697) and the 5 HIV1 KS2 patients with high HHV-8
antibodies have a mean CD41 T-cell level of 130 (range
49–295), this suggested that the detection of higher lev-
els of HHV-8 antibodies in the 5 patients may not be due
to the immunocompetent status of these individuals.
However, for a meaningful correlation and to determine
whether immunosuppression is a potential confounder,
HIV1 patients with low and high HHV-8 antibodies de-
scribed here need to be monitored sequentially for the
levels of HHV-8 antibodies, HHV-8 DNA, CD41 T-cell
levels, HIV levels, and for the development of KS; such
prospective studies are currently in progress. HHV-8
reactivation probably occurs under reduced immunosur-
veillence conditions as a result of ongoing HIV infection.
Regression of KS after withdrawal of immunosuppres-
sive therapy in transplantation individuals (Safai and
Schwartz, 1992) shows the important role of the immune
system in controlling KS and possibly HHV-8. Recent
reports show that foscarnet and ganciclovir may have
some activity in preventing KS (Mocroft et al., 1996).
Since these drugs are effective against lytic virus repli-
cation, this also indirectly suggests that HHV-8 lytic rep-
lication may have a role in KS and may precede KS
development. However, a better understanding of the
serological responses against HHV-8 latent and lytic
antigens and their correlation with KS development and
progression is critical. If HHV-8 lytic replication indeed
precedes the development of KS, then the measurement
of lytic antibody responses could serve as a diagnostic
and/or prognostic marker for tumor development and/or
regression and might have important implications in the
assessment of therapeutic intervention of lytic HHV-8
infection.
MATERIALS AND METHODS
Cell lines
HHV-82 and EBV2 body cavity B-cell lymphoma cell
line BCBL-1 (Renne et al., 1996), HHV-81 and EBV1
HBL-6 cells (Moore et al., 1996a), EBV producer cell line
P3HR-1, and EBV2 B-cell line BJAB were grown in RPMI
1640 medium with glutaMAX I (Gibco-BRL) supple-
mented with 10% heat-inactivated fetal bovine serum and
antibiotics. The BCBL-1 cells were a gift from Dr.
McGrath (UCLA) and the HBL-6 cells were a gifts from
Dr. P. Moore (Columbia University, NY). Single cell clones
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from HBL-6 cells (HHV-81, EBV1) were established by
limiting dilutions and were tested by PCR for HHV-8 and
EBV DNA using primers as described before (Smith et al.,
1997) and by IFA for EBV and HHV-8 using human sera
(Smith et al., 1997). Three types of clones were obtained:
HHV-81, EBV1, HHV-82 EBV1; and HHV-82, EBV2.
These were recloned and retested. The cell lines desig-
nated D6 and C6 (HHV-82 and EBV2) were used as
controls for the experiments described here.
DNA extraction
Details of collection of DNA from peripheral blood
specimens, primers amplifying HHV-8 DNA sequences,
primers amplifying regions internal to the outer primers,
and sequences of internal probes used for Southern blot
hybridization were as described before (Koelle et al.,
1997; Smith et al., 1997). Several precautions were taken
to avoid contamination in PCR reactions. Extractions
were done in a location having no cloned or amplified
materials corresponding to the genes detected by PCR.
Cells were extracted for DNA in a laboratory in another
building, using materials dedicated to this purpose, and
PCR reactions were set up using filter tips and separate
materials in a different laboratory from that used for
analysis of cloned and amplified materials.
Serum samples
Forty-four sera from HIV1 KS1 adult men patients, 47
sera from HIV1 KS2 patients (homosexual men), 120
sera from age-matched HIV2 and KS2 adult men, and
110 sera from children (ages 1 to 5) were used in these
studies. All sera were stored at 220°C and heat inacti-
vated at 56°C for 30 min before use.
Immunofluorescence assay (IFA)
IFA was done according to procedures described be-
fore (Smith et al., 1997). Briefly, 107 cells in 10 ml medium
were induced with 20 ng/ml of phorbol ester (TPA; Sigma,
St. Louis, MO). Uninduced and TPA-induced BCBL-1
cells, TPA-induced P3HR-1 cells, and TPA-induced BJAB
cells were collected, washed in phosphate-buffered sa-
line, pH 7.4 (PBS), spotted on slides (5 mm inner diam-
eter, 10 circles per slide), air dried in a laminar flow hood
under UV light, and fixed in cold acetone for 10 min. Fixed
cells were incubated for 30 min at 37°C with twofold
dilutions of human sera beginning at 1:10. After incuba-
tion, slides were washed rigorously in PBS. The slides
were then incubated for 30 min at 37°C with a prestan-
dardized dilution of fluorescein isothiocyanate (FITC)-
conjugated goat anti-human IgG (Hyclone, Logan, UT).
After washing, the slides were counterstained with a
1:20,000 dilution of Evans blue (Sigma) for 5 min at room
temperature, washed, and mounted with 50% (vol/vol)
glycerol in PBS. Slides were examined under a fluores-
cence microscope.
Radiolabeling, radioimmunoprecipitation (RIP), and
sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE)
Uninduced and TPA-induced (72–96 h postinduction)
cells (107) were labeled for 20 h with 250 mCi of [35S]me-
thionine and cysteine (Tran35S-label, sp act, 1177 Ci/
mmol; ICN, Irvine, CA) or with 500 mCi of [3H]glu-
cosamine (sp act, 25 Ci/mmol; American Radiolabeled
Chemicals Inc., St. Louis) in deficient DMEM (Sigma).
Immunoprecipitation was carried out according to pro-
cedures described before (Balachandran et al., 1989;
Chang and Balachandran, 1991; Smith et al., 1997).
Briefly, cells were solubilized with lysing buffer (0.05 M
Tris–hydrochloride, pH 7.5, 0.15 M NaCl, 1% sodium de-
oxycholate, 1% Triton X-100, 100 U of aprotinin/ml, 0.1 mM
phenylmethylsulfonyl fluoride), sonicated, and centri-
fuged at 100,000 g for 1 h. Equal trichloroacetic acid-
precipitable counts (5 3 105 cpm) of cell lysates were
mixed with 10 ml of antibodies and 100 ml of Protein-A–
Sepharose beads (Pharmacia; Piscataway, NJ) and were
kept rocking at 4°C for 2 h. The precipitates were
washed, dissociated by boiling in sample buffer, and
analyzed by SDS–PAGE in 9–12% acrylamide cross-
linked with 0.28% N, N9-diallyltartardiamide (DATD; Sig-
ma). Molecular weight markers (Sigma) were electropho-
resed in parallel channels. Gels were stained, destained,
infused with 1 M salicyclic acid, dried on filter paper, and
placed in contact with XAR-5 film (Kodak; Rochester, NY)
at 270°C for fluorography.
Construction of cDNA library and screening
of lambda ZAPII expression system
Total RNA extracted from TPA-induced BCBL-1 cells
(24, 48, 72, and 96 h postinduction) were treated with
DNase and verified for the absence of HHV-8 DNA by
DNA-PCR using ORF 22, 25, and 26 primers (Smith et al.,
1997). The mRNA was isolated by oligotex mRNA isola-
tion kit (Qiagen, Chatsworth, CA) and the purified mRNAs
were used in cDNA synthesis using oligo(dT) linker–
primer containing a XhoI site (Stratagene, La Jolla, CA)
according to the manufacturer’s recommendations. Syn-
thesized cDNAs were tested for HHV-8 messages by
PCR for HHV-8 ORFs 22, 25, and 26 using primers de-
scribed before (Smith et al., 1997) and appropriate size
fragments were detected. The cDNA library in the
Lambda ZAPII expression system was made according
to the manufacturer’s recommendations. After amplifica-
tion, this library had a titer of about 4 3 109 PFU with 99%
recombinant phages. This library was screened with a
HIV1 KS1 serum using procedures described before
(Chang and Balachandran, 1991). To remove nonspecific
reactivities, the serum was absorbed with HHV-82 con-
trol B cells (D6 and BJAB) and with bacterial lysates with
nonrecombinant phages. Appropriate dilution of the an-
tibody was used to screen the library. Immunoreactive
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phages were picked and purified by four subsequent
steps of screening. After four screenings, 56 clones were
isolated. The identified cDNAs were released into the
plasmid forms by in vivo excision using the ExAssist
helper phage.
DNA sequence analysis
The cDNA clones (both orientations) were sequenced
in the Biotechnology Center at the University of Kansas
Medical Center. Sequences were analyzed and com-
pared with the data bank by the BLAST program.
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